TCT 781: Clinical outcomes of patients treated using 1-month dual antiplatelet therapy after biodegradable-polymer DES implantation

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott; Boston Scientific Corporation; Terumo Medical Corporation; Daiichi-Sankyo; Japan Lifeline; OrbusNeichi